Skip to main content
Erschienen in: Breast Cancer 2/2011

01.04.2011 | Original Article

Radiofrequency ablation of breast cancer: a comparative study of two needle designs

verfasst von: Wai Ka Hung, Kong Ling Mak, Marcus Ying, Miranda Chan

Erschienen in: Breast Cancer | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Radiofrequency ablation (RFA) is an emerging minimally invasive technique for breast cancer treatment. There are two different needle designs. One is to deploy a series of arrays to allow an even distribution of heat within the tumor. A new design is a straight needle with continuous infusion of cold saline to prevent charring and ensure continuous heat delivery. We report the first comparative study using two different needles for ablation of breast cancer.

Methods

Chinese patients with breast cancer less than 2 cm were prospectively recruited. Multifocal tumor was excluded. RFA was performed under general anesthesia following sentinel node biopsy. Sequential allocation was used. In the first group, tumor was ablated by using the LeVeen needle. Cool-tip needle was used in the subsequent group. The tumor was then resected. Tumor viability was assessed by nicotinamide adenine dinucleotide-diaphorase (NADH) staining. Complete ablation rate was compared. Evidence of thermal damage to the skin was also assessed.

Results

Twenty patients were recruited. Mean tumor size was 14 mm. Complete ablation rate was the same (90% versus 89% for the Cool-tip and the LeVeen, respectively). Cool-tip has a shorter ablation time when compared with LeVeen (12 versus 28 min), and the Cool-tip needle was found to be easier to insert. There was no visible skin burn after RFA.

Conclusions

Cool-tip and LeVeen systems had the same efficacy in ablation of breast cancer, but Cool-tip was easier to insert and had a shorter ablation time.
Literatur
1.
Zurück zum Zitat Hung WK, Ying M, Chan CM, Lam HS, Mak KL. Minimally invasive technology in the management of breast disease. Breast Cancer. 2009;16(1):23–9.PubMedCrossRef Hung WK, Ying M, Chan CM, Lam HS, Mak KL. Minimally invasive technology in the management of breast disease. Breast Cancer. 2009;16(1):23–9.PubMedCrossRef
2.
Zurück zum Zitat Simmons RM. Ablative techniques in the treatment of benign and malignant breast disease. J Am Coll Surg. 2003;197(2):334–8.PubMedCrossRef Simmons RM. Ablative techniques in the treatment of benign and malignant breast disease. J Am Coll Surg. 2003;197(2):334–8.PubMedCrossRef
3.
Zurück zum Zitat van Esser S, van den Bosch MA, van Diest PJ, Mali WT, Borel Rinkes IH, Van Hillegersberg R. Minimally invasive ablative therapies for invasive breast carcinomas: an overview of current literature. World J Surg. 2007;31(12):2284–92.PubMedCrossRef van Esser S, van den Bosch MA, van Diest PJ, Mali WT, Borel Rinkes IH, Van Hillegersberg R. Minimally invasive ablative therapies for invasive breast carcinomas: an overview of current literature. World J Surg. 2007;31(12):2284–92.PubMedCrossRef
4.
Zurück zum Zitat Oura S, Tamaki T, Yoshimasu T, Ohta F, Nakamura R, Okamura Y. Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size. Breast Cancer. 2007;14(1):48–54.PubMedCrossRef Oura S, Tamaki T, Yoshimasu T, Ohta F, Nakamura R, Okamura Y. Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size. Breast Cancer. 2007;14(1):48–54.PubMedCrossRef
5.
Zurück zum Zitat Goldberg SN, Gazelle GS, Solbiati L, Rittman WJ, Mueller PR. Radiofrequency tissue ablation: increased lesion diameter with a perfusion electrode. Acad Radiol. 1996;3(8):636–44.PubMedCrossRef Goldberg SN, Gazelle GS, Solbiati L, Rittman WJ, Mueller PR. Radiofrequency tissue ablation: increased lesion diameter with a perfusion electrode. Acad Radiol. 1996;3(8):636–44.PubMedCrossRef
6.
Zurück zum Zitat Hung WK, Chan CM, Ying M, Chong SF, Mak KL, Yip AW. Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg. 2005;92(12):1494–7.PubMedCrossRef Hung WK, Chan CM, Ying M, Chong SF, Mak KL, Yip AW. Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg. 2005;92(12):1494–7.PubMedCrossRef
7.
Zurück zum Zitat Izzo F, Thomas R, Delrio P, Rinaldo M, Vallone P, DeChiara A, et al. Radiofrequency ablation in patients with primary breast carcinoma: a pilot study in 26 patients. Cancer. 2001;92:2036–44.PubMedCrossRef Izzo F, Thomas R, Delrio P, Rinaldo M, Vallone P, DeChiara A, et al. Radiofrequency ablation in patients with primary breast carcinoma: a pilot study in 26 patients. Cancer. 2001;92:2036–44.PubMedCrossRef
8.
Zurück zum Zitat Jeffrey SS, Birdwell RL, Ikeda DM, Daniel BL, Nowels KW, Dirbas FM, et al. Radiofrequency ablation of breast cancer: first report of an emerging technology. Arch Surg. 1999;134:1064–8.PubMedCrossRef Jeffrey SS, Birdwell RL, Ikeda DM, Daniel BL, Nowels KW, Dirbas FM, et al. Radiofrequency ablation of breast cancer: first report of an emerging technology. Arch Surg. 1999;134:1064–8.PubMedCrossRef
9.
Zurück zum Zitat Burak WE Jr, Agnese DM, Povoski SP, Yanssens TL, Bloon KJ, Wakely PE, et al. Radiofrequency ablation of invasive breast carcinoma followed by delayed surgical excision. Cancer. 2003;98:1369–76.PubMedCrossRef Burak WE Jr, Agnese DM, Povoski SP, Yanssens TL, Bloon KJ, Wakely PE, et al. Radiofrequency ablation of invasive breast carcinoma followed by delayed surgical excision. Cancer. 2003;98:1369–76.PubMedCrossRef
10.
Zurück zum Zitat Hayashi AH, Silver SF, van der Westhuizen NG, Donald JC, Parker C, Fraser S, et al. Treatment of invasive breast carcinoma with ultrasound-guided radiofrequency ablation. Am J Surg. 2003;185:429–35.PubMedCrossRef Hayashi AH, Silver SF, van der Westhuizen NG, Donald JC, Parker C, Fraser S, et al. Treatment of invasive breast carcinoma with ultrasound-guided radiofrequency ablation. Am J Surg. 2003;185:429–35.PubMedCrossRef
11.
Zurück zum Zitat Fornage BD, Sneige N, Ross MI, Mirza AN, Kuerer HM, Edeiken BS, et al. Small breast cancer treated with US-guided radiofrequency ablation: feasibility study. Radiology. 2004;231:215–24.PubMedCrossRef Fornage BD, Sneige N, Ross MI, Mirza AN, Kuerer HM, Edeiken BS, et al. Small breast cancer treated with US-guided radiofrequency ablation: feasibility study. Radiology. 2004;231:215–24.PubMedCrossRef
12.
Zurück zum Zitat Khatri VP, McGahan JP, Ramsamooj R, Griffey S, Brock J, Cronan M, et al. A phase II trial of image-guided radiofrequency ablation of small invasive breast carcinomas: use of saline-cooled tip electrode. Ann Surg Oncol. 2007;14:1644–52.PubMedCrossRef Khatri VP, McGahan JP, Ramsamooj R, Griffey S, Brock J, Cronan M, et al. A phase II trial of image-guided radiofrequency ablation of small invasive breast carcinomas: use of saline-cooled tip electrode. Ann Surg Oncol. 2007;14:1644–52.PubMedCrossRef
13.
Zurück zum Zitat Medina-Franco H, Soto-Germes A, Ulloa-Gomez JL, Romero-Trejo C, Uribe N, Ramirez-Alvarado CA, et al. Radiofrequency ablation of invasive breast carcinoma: a phase II trial. Ann Surg Oncol. 2008;15(6):1689–95.PubMedCrossRef Medina-Franco H, Soto-Germes A, Ulloa-Gomez JL, Romero-Trejo C, Uribe N, Ramirez-Alvarado CA, et al. Radiofrequency ablation of invasive breast carcinoma: a phase II trial. Ann Surg Oncol. 2008;15(6):1689–95.PubMedCrossRef
14.
Zurück zum Zitat Earashi M, Noguchi M, Motoyoshi A, Fujii H. Radiofrequency ablation therapy for small breast cancer followed by immediate surgical resection or delayed mammotome excision. Breast Cancer. 2007;14(1):39–47.PubMedCrossRef Earashi M, Noguchi M, Motoyoshi A, Fujii H. Radiofrequency ablation therapy for small breast cancer followed by immediate surgical resection or delayed mammotome excision. Breast Cancer. 2007;14(1):39–47.PubMedCrossRef
15.
Zurück zum Zitat Susini T, Nori J, Olivieri S, Livi L, Bianchi S, Mangialavori G, et al. Radiofrequency ablation for minimally invasive treatment of breast carcinoma. A pilot study in elderly inoperable patients. Gyn Oncol. 2007;104:304–10.CrossRef Susini T, Nori J, Olivieri S, Livi L, Bianchi S, Mangialavori G, et al. Radiofrequency ablation for minimally invasive treatment of breast carcinoma. A pilot study in elderly inoperable patients. Gyn Oncol. 2007;104:304–10.CrossRef
16.
Zurück zum Zitat Marcy PY, Magne N, Castadot P, Bailet C, Namer M. Ultrasound-guided percutaneous radiofrequency ablation in elderly breast cancer patients: preliminary institutional experience. Br J Radiol. 2007;80:267–73.PubMedCrossRef Marcy PY, Magne N, Castadot P, Bailet C, Namer M. Ultrasound-guided percutaneous radiofrequency ablation in elderly breast cancer patients: preliminary institutional experience. Br J Radiol. 2007;80:267–73.PubMedCrossRef
17.
Zurück zum Zitat Quaranta V, Manenti G, Bolacchi F, Cossu E, Pistolese CA, Buonomo OC, et al. FEM analysis of RF breast ablation: multiprobe versus cool-tip electrode. Anticancer Res. 2007;27(2):775–84.PubMed Quaranta V, Manenti G, Bolacchi F, Cossu E, Pistolese CA, Buonomo OC, et al. FEM analysis of RF breast ablation: multiprobe versus cool-tip electrode. Anticancer Res. 2007;27(2):775–84.PubMed
18.
Zurück zum Zitat Kontos M, Felekouras E, Fentiman IS. Radiofrequency ablation in the treatment of primary breast cancer: no surgical redundancies yet. Int J Clin Pract. 2008;62(5):816–20.PubMedCrossRef Kontos M, Felekouras E, Fentiman IS. Radiofrequency ablation in the treatment of primary breast cancer: no surgical redundancies yet. Int J Clin Pract. 2008;62(5):816–20.PubMedCrossRef
Metadaten
Titel
Radiofrequency ablation of breast cancer: a comparative study of two needle designs
verfasst von
Wai Ka Hung
Kong Ling Mak
Marcus Ying
Miranda Chan
Publikationsdatum
01.04.2011
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 2/2011
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-009-0181-1

Weitere Artikel der Ausgabe 2/2011

Breast Cancer 2/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.